Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSC and rEMS for Toxic Optic Neuropathy
NCT04877067Phase 3Completed
- Sponsor
- Ankara Üniversitesi Teknokent
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of wharton's jelly mesenchymal stromal cells in toxic optic neuropathy (TON), sponsored by Ankara Üniversitesi Teknokent. Started Apr 2019; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
toxic optic neuropathy (TON)
Beyond the preview
Go deeper on NCT04877067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877067.